Vitamin Therapy for Prevention of Stroke
Vitamin Intervention for Stroke Prevention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston Salem, North Carolina, United States, 27157-1068
- Wake Forest University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any stroke (non-disabling cerebral infarction, NDCI) < 120 days prior to randomization
- Symptoms lasting > 24 hrs, or if < 24 hrs, CT or MRI shows new infarction at expected site
- Modified Rankin score < 3
- Homocysteine level > the 25th percentile, ie, 9.5 mol/L for men, and 8.5 mol/L for women
- Patient compliance with multivitamin during run-in phase > 75%
Exclusion Criteria:
- Stroke due to: intracranial hemorrhage, dissection of a cervico-cephalic artery, veno-occlusive disease, drug abuse, vasculitis
- CT or MRI shows lesion other than infarction as cause of syndrome
- Modified Rankin score of 4 or 5 at eligibility
- Presence of potential sources of cardiogenic emboli: atrial fibrillation, prosthetic cardiac valve, intracardiac thrombus or neoplasm, valvular vegetation
- Neurologic illness other than stroke that would prevent proper evaluation of recurrent stroke
- Illness that limits life expectancy to < 2 years
- Severe congestive heart failure
- Renal insufficiency requiring dialysis
- Untreated B12 deficiency or untreated pernicious anemia
- Uncontrolled hypertension (systolic >185 mm/Hg or diastolic >105 mm/Hg on two readings separated by 5 min.) at eligibility
- Conditions preventing reliable participation in study: refractory depression, severe cognitive impairment, alcoholism, other substance abuse
- Medications given within last 30 days that affect homocysteine: methotrexate, tamoxifen, L-dopa, phenytoin, or bile acid sequestrants that can decrease folate levels
- Women of childbearing potential
- Patients receiving active intervention in another trial
- Patients on multi-vitamins, single B6, or folic acid, unless willing to discontinue and take study supplement
- Any surgical procedure, invasive cardiac instrumentation, endarterectomy, stent placement, thrombectomy or other endovascular treatment of abnormal carotid artery performed within 30 days prior to randomization or scheduled within 30 days after randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James F. Toole, M.D., Wake Forest University
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Brain Infarction
- Myocardial Infarction
- Infarction
- Stroke
- Cerebral Infarction
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Hematinics
- Folic Acid
- Vitamin B 12
- Hydroxocobalamin
- Pyridoxine
Other Study ID Numbers
Other Study ID Numbers
- R01NS034447 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.